Speaker illustration

Doctor Matthias M Engelen

University Hospitals (UZ) Leuven, Leuven (Belgium)

After being a young professional athlete, he started med school in 2010. He graduated as a medical doctor in 2017 whereafter he got trained in internal medicine as a junior doctor. His master dissertation looked into the clinical use and consequences of thrombolytic therapy, showing his interest in thrombosis and haemostasis. Just recently, he started working on coagulation in cardiovascular diseases as a PhD researcher.

Heparin is more effective than apixaban in inhibiting in vitro contact activated coagulation

Event: ESC Congress 2020

Topic: Platelets, Haemostasis, Coagulation

Session: Role of Platelets, Inflammation and Endothelial Cells in Vascular Dysfunction


Trends in indications and outcome in thrombolytic therapy: a retrospective single center study

Event: ESC Congress 2019

Topic: Cardiovascular Pharmacotherapy

Session: Cardiovascular pharmacotherapy


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb